Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-08 · accession 0001835458-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-08 | KNSA | Ragosa Mark | CFO | S - Sale | $41.89 | -12.0K | 19.1K | -39% | -$502.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2026-01-08 | S | D | 12,000 | $41.89 | 19,086 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |